Psychological Impact of Quarantine in Rheumatoid Arthritis Patient During COVID-19 Outbreak (PRPsyCOVID)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04351399 |
Recruitment Status :
Completed
First Posted : April 17, 2020
Last Update Posted : December 11, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Clinical data about psychological impact of quarantine are well studied in transient event or more prolonged situation like jail incarceration.
In recent metaanalysis, psychological impact of quarantine was well documented in a specific population during first SARS epidemy. Even after the end of quarantine several patients were still with symptom of avoiding mainly agoraphobia, frequent hand washing and a carefull return to normal life COVID-19 infection is already associated with psychological symptom like anxiety, depression, sleep disorders and symptoms of acute stress However psychological impact of quarantine is on none in chronic painful inflammatory rheumatism in France. The prevalence of rheumatoid arthritis is 0.5% of the population with frequent comorbidity such as anxiety and depression.
During the quarantine secondary to COVID-19 pandemic it's possible to evaluated the psychological impact of adult RA patients.
The present study is an "emergency" being realize before the end of the quarantine.
Condition or disease | Intervention/treatment |
---|---|
Sars-CoV2 Rheumatic Diseases Rheumatoid Arthritis Chronic Pain | Other: questionnaire assesment |
Study Type : | Observational |
Actual Enrollment : | 318 participants |
Observational Model: | Family-Based |
Time Perspective: | Cross-Sectional |
Official Title: | Psychological Impact of Quarantine in Rheumatoid Arthritis Patient During COVID-19 Outbreak |
Actual Study Start Date : | April 27, 2020 |
Actual Primary Completion Date : | May 4, 2020 |
Actual Study Completion Date : | May 4, 2020 |

Group/Cohort | Intervention/treatment |
---|---|
patient with chronic painful inflammatory rheumatism |
Other: questionnaire assesment
The questionnaire will ask questions around their socio-demographic characteristics,quality of life, painful, using analgesic , since they are in quarantine |
- Frequency of RA patients with emotional impact (feeling of isolation) [ Time Frame: maximum 1 week from baseline on ]
- self-reported questionnaire for painful [ Time Frame: maximum 1 week from baseline on ]Self reported questionnaire with questions to assess the characteristic,intensity of pain on quality of life, and consumption of analgesic.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- Rheumatoid arthritis Quarantine
Exclusion Criteria:
- Non adult patient RA patient without quarantine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04351399
France | |
Hopital Roger Salengro, CHU Lille | |
Lille, France, 59037 |
Principal Investigator: | René-Marc FLIPO, MD,PhD | University Hospital, Lille |
Responsible Party: | University Hospital, Lille |
ClinicalTrials.gov Identifier: | NCT04351399 |
Other Study ID Numbers: |
2020_29 2020-A00907-32 ( Other Identifier: ID-RCB number,ANSM ) |
First Posted: | April 17, 2020 Key Record Dates |
Last Update Posted: | December 11, 2020 |
Last Verified: | April 2020 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Psychological impact COVID-19 Rheumatoid arthritis |
Arthritis Arthritis, Rheumatoid Rheumatic Diseases Collagen Diseases Chronic Pain Joint Diseases |
Musculoskeletal Diseases Connective Tissue Diseases Autoimmune Diseases Immune System Diseases Pain Neurologic Manifestations |